Answers are grounded in this paper and cite their sources.
Evaluates hematologic effects of selumetinib in children, suggesting minimal clinically significant changes.
Selumetinib, a mitogen‐activated protein kinase kinase inhibitor, was the first Food and Drug Administration‐approved treatment for children with neurofibromatosis type 1‐associated inoperable plexiform neurofibromas. We evaluated hematologic effects in 98 pediatric participants from the SPRINT Phase 1/2 trial (NCT01362803) with a median follow‐up of 5.1 years (range: 0.2–11 years). Over 90% of values for white blood cell count, platelet count, absolute neutrophil count, and absolute lymphocyte count remained within normal limits across timepoints. There was a statistically significant, but unlikely clinically significant, decrease in absolute lymphocyte count and an increase in mean corpuscular volume. Selumetinib was not associated with apparent clinically significant hematologic changes.
No takes yet. Share an insight, caveat, or question.
Siegel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: